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Abstract 
Phytol (PYT) is a diterpene member of the long-chain unsaturated acyclic alcohols. PYT and 
some of its derivatives, including phytanic acid (PA), exert a wide range of biological effects. 
PYT is a valuable essential oil (EO) used as a fragrance and a potential candidate for a broad 
range of applications in the pharmaceutical and biotechnological industry. There is ample 
evidence that PA may play a crucial role in the development of pathophysiological states. 
Focusing on PYT and some of its most relevant derivatives, here we present a systematic review 
of reported biological activities, along with their underlying mechanism of action. Recent 
investigations with PYT demonstrated anxiolytic, metabolism-modulating, cytotoxic, 
antioxidant, autophagy- and apoptosis-inducing, antinociceptive, anti-inflammatory, immune-
modulating, and antimicrobial effects. PPARs- and NF-κB-mediated activities are also discussed 
as mechanisms responsible for some of the bioactivities of PYT. The overall goal of this review 
is to discuss recent findings pertaining to PYT biological activities and its possible applications.  
 
 
Keywords: phytol; phytol metabolites; phytanic acid; plant-derived compounds; biological 
activities.  
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INTRODUCTION 
Phytol (PYT; 3,7,11,15-tetramethylhexadec-2-en-1-ol) is a compound found abundantly 
in nature. Being a part of the chlorophyll molecule, it is produced by almost all photosynthetic 
organisms, including algae (de Souza and Nes, 1969), plants (Ischebeck et al., 2006), and 
bacteria (cyanobacteria) (Proteau, 1998). It is additionally formed as an important metabolite 
during catabolism in ruminant animals. Consequently, PYT is considered as the most abundant 
acyclic isoprenoid present in the biosphere of our planet (Rontani and Volkman, 2003). In 
ruminants, gut digestion of consumed plant materials releases PYT, which once converted into 
phytanic acid (PA), is eventually stored in fat depositions (Islam et al., 2015; van den Brink and 
Wanders, 2006). 
While PYT is primarily used as a fragrance constituent, its significant biological 
properties have recently drawn the attention for possible application in the pharmaceutical and 
biotechnological fields. Although large experimental data sets have addressed PYT metabolism, 
PA oxidation, and pathophysiological contributions of plasma PA levels, the exact molecular 
mechanisms underlying its biological actions are still insufficiently understood.  
In this review, we summarize an updated and detailed overview of PYT and its 
derivatives based on the most recent available literature with emphasis on possible mechanisms 
of action of reported bioactivities, and future prospects pharmaceutical and biotechnological 
applications.  
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
METABOLISM OF PYT AND PYT-DERIVATIVES 
The metabolic degradation pathway of PYT is complex and has been recently described 
in details (Ischebeck et al., 2006; Islam et al., 2015). An overview of the overall pathway, along 
with the work of Ischebeck et al. on the metabolic fate of PYT in Arabidopsis, is depicted in 
Figure 1 (Ischebeck et al., 2006). 
PA as a primary PYT biometabolite, has been known for decades (Gloerich et al., 2007; 
Steinberg et al., 1966). However, the biochemical pathway of conversion between PYT and PA 
has not been completely characterized. Based on a comprehensive literature review, Wanders et 
al. (2011) have recently proposed a PYT degradation pathway: Briefly, PYT is first oxidized to 
phytenal by alcohol dehydrogenase (ADH), followed by oxidation to PA (Steinberg et al., 1966; 
Wanders et al., 2011). Based on a previous study on rat liver, van den Brink and coworkers 
proposed that PA is converted first to phytenoyl-CoA by acyl-CoA synthetase, followed by the 
action of enoyl-CoA reductase, which is located in the peroxisomal and microsomal fractions of 
the liver (van den Brink et al., 2005; Wanders et al., 2011). In addition, the peroxisomal enzyme 
trans-2-enoyl-CoA reductase (TER), encoded by the PECR gene, can convert phytenoyl-CoA to 
phytanoyl-CoA (Gloerich et al., 2006), which then undergoes α-oxidation in peroxisomes to give 
rise to pristanic acid.  
α-Oxidation of PA requires the catalytic participation of different enzymes and yields 
pristanoyl-CoA, which is considered to be the starting product of other oxidative pathways 
(Wanders et al., 2011). In addition to the participating enzymes, diverse transporters play an 
important role in the oxidation process since the semi-permeable peroxisomal membranes allow 
compounds with molecular weights between 300 and 400 Da, to pass through the PXMP2 gene 
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product, whereas larger molecules such as phytanoyl-CoA, require certain carrier proteins, 
including PMP34 for ATP.  
Upon undergoing three cycles of β-oxidation in peroxisomes, pristanoyl-CoA further 
produces 4,8-dimethylnonanoyl-CoA, propionyl-CoA, and acetyl-CoA. Eventually, the products 
of a pristanoyl-CoA β-oxidation are shuttled by distinct pathways (carnitine-dependent and 
carnitine-independent) to mitochondria for further oxidation.  
β-Oxidation of PA is in general restricted due to the presence of a methyl (-CH3) group at 
the C3-position of the structure. Higher levels of plasma PA are observed in association with a 
type of hereditary disorder called Refsum's disease (RD) (Gloerich et al., 2006; Gloerich et al., 
2007; Islam et al., 2015). Urine of RD patients contains 3-methyladipic acid and 3,6-
dimethyloctanedioic acid, which are believed to be intermediates resulting from ω-oxidation of 
PA. In addition, a study conducted with a mouse model, in which the gene encoding for 
phytanoyl-CoA 2-hydroxylase was disrupted, revealed a possible pathway for ω-oxidation of PA 
(Wanders et al., 2011). In brief, ω-oxidation of PA produces phytane-1,16-dioic acid, later 
degraded by β-oxidation from the ω-end, resulting in different acyl-CoA esters and respective 
free fatty acids (upon thioesterase-mediated cleavage of the CoA esters) (Wanders et al., 2011) 
(Figure 2). 
 
ANTIMICROBIAL AND CYTOTOXIC ACTIVITIES 
PYT is one of the major constituents of plant derived essential oils (EO) and much 
research has been done to prove that the antimicrobial or cytotoxic activity observed for those 
EOs is related to their phytol content. The general antimicrobial potential of EOs is well-
established and well-documented (Murbach Teles Andrade et al., 2014; Prabuseenivasan et al., 
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2006), but the underlying mechanisms are still often insufficiently understood. It is hypothesized 
that the mechanism of the antimicrobial activity might be related to the ability of lipophilic 
molecules to cross cell membranes and exert their inhibitory activity on multiple targets 
simultaneously. PYT’s antimicrobial activity was reported against Escherichia coli (growth 
inhibition MIC 62.5 µg/mL) (Ghaneian et al., 2015) and Pseudomonas aeruginosa (growth 
inhibition MIC 19 µg/mL) (Pejin et al., 2015). It is well-documented that proteins and nucleic 
acids are important bacterial macromolecular targets of antibacterial agents. Proteins play a 
variety of structural and functional roles, whereas nucleic acids carry mainly genetic information 
(Zhang et al., 2016). Accordingly, any alteration or damage to these cellular components might 
enhance growth inhibition or induce cell death. According to previous works on PYT and PYT-
derivatives (Ghaneian et al., 2015; Inoue et al., 2005; Saikia et al., 2010; Singh et al., 2012) the 
action against Mycobacterium tuberculosis and Staphylococcus aureus appears to have no 
specific cellular target. In addition, research findings related to eight bacterial and eight fungal 
strains (Pejin et al., 2014b) suggested that PYT exhibits broad-spectrum of antimicrobial effects. 
Pejin and co-workers investigated the in vitro antibacterial activity of PYT against three species 
of infective endocarditis (IE) bacteria, namely, Clostridium sporogenes, Sarcina lutea, and 
Enterococcus faecalis (Pejin et al., 2014a). Results revealed that PYT displays significant 
activity against all tested bacteria, with Enterococcus faecalis being the most susceptible (growth 
inhibition MIC < 2 µg/mL) (Pejin et al., 2014a). In addition, pivaloyl, cinnamoyl, 3,4,5-
trimethoxybenzoyl, 2,3-dichlorobenzoyl, and aldehyde derivatives of PYT exhibited drug 
resistance reversal activity against two E. coli strains, potentiating up to 16-fold the efficacy of 
tested antibiotics (Upadhyay et al., 2014). 
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PYT-containing EOs were postulated to dysregulate the function of eukaryotic cells 
through a number of effects including disruption of membrane permeability and depolarization 
of the mitochondrial membrane (Bakkali et al., 2008). Consequently, ionic Ca2+ cycling and 
channels for other ions become affected, together with proton pump and the ATP pool changes. 
Reduction of the pH gradient and changes in the fluidity of membranes are involved in the mode 
of action of EOs in general, with the membranes becoming abnormally permeable. Taken all 
together, these processes lead to leakage of radicals, cytochrome C, Ca2+, and diverse proteins, 
similar to conditions involving oxidative stress and failure of the cell bioenergetics. Furthermore, 
permeabilization of outer and inner mitochondrial membranes essentially causes cell death by 
apoptosis and necrosis. Additionally, subsequent processes can have a prooxidative action, 
causing the late onset of both apoptosis and necrosis. Such effects might be underlying the 
activity of PYT against eukaryotic microorganisms such as Candida albicans and Aspergillus 
niger (Ghaneian et al., 2015).  
The difference in electric potential between the interior and exterior cellular membrane is 
an important parameter associated with the cytotoxic activity. Treatments that alter the 
membrane potential (MP) can also change cellular functions. Agents, such as carbonyl cyanide-
m-chlorophenylhydrazone (Zhang et al., 2016), that cause the MP of bacteria to approach or 
become zero, can lead to irregular cellular metabolism, and finally, cell death. EOs, particularly 
when applied at high concentrations, are known to readily cross the cell and mitochondrial 
membranes. In addition to membrane disruption and loss of essential cellular materials, EOs in 
general, often exert oxidative effects on the cells, which might result in damage to 
macromolecules such as proteins, lipids, and DNA (Faix et al., 2007). In a similar fashion, a 
concentration-dependent action of PYT was observed with respect to the cytotoxic activity 
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detected in Schistosoma mansoni (de Moraes et al., 2014), where PYT at concentrations of 50, 
75 and 100 µg/mL produces more anti- S. mansoni activity than that of 25 µg/mL. In a study by 
da Silva and colleagues, it was shown that the PYT rich hexane fraction of the leaves of 
Lacistema pubescens exerts anti-promastigote activity at both the promastigote and amastigote 
forms of Leishmania amazonensis with IC50 values of 44.0 and 25.8 µg/mL, respectively (da 
Silva et al., 2015).  
To date, there have been several studies on the cytotoxic activity of PYT, e.g., in S. 
mansoni (de Moraes et al., 2014) and lymphoid leukemia Molt 4B cells (Komiya et al., 1999). 
Research findings suggest that PA can disrupt redox homeostasis which results in astrogliosis in 
rat cerebellum. Additionally, production of reactive nitrogen species (RNS) is believed to 
contribute to the observed cerebellum alterations. Such a state is commonly observed in patients 
affected by RD and related phenomena, associated with the accumulation of PA (Borges et al., 
2015). Similarly, PA at a concentration of 50 µM was shown to induce rotenone-like oxidative 
stress via a direct action on mitochondria (Schönfeld and Reiser, 2006). In addition, PA at a 
concentration of 10 µM causes cell death of neuroblastoma Neuro2a cells via activation of 
Hdac2 and Hdac3 (Nagai, 2015). Both of these studies suggested that the cytotoxic activity of 
PA is concentration dependent, and that different mechanisms contribute to the cell death. 
Moreover, PYT from Citrullus lanatus (watermelon) sprouts inhibited the growth of human T-
cell leukemia (Jurkat) and counteracted tumor development in a xenograft model of human lung 
adenocarcinoma in mice (Itoh et al., 2018). PYT action was associated with S-phase cell cycle 
arrest and increased intracellular ROS production in the studied Jurkat cells. It also decreased the 
expression of cyclins A and D and the suppressed MAPK and PI3K/Akt signaling (Itoh et al., 
2018). PYT also showed cytotoxic response with an IC50 value of 16.97 µM in human lung 
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carcinoma cells (A549) and caused characteristic apoptotic morphological changes and enhanced 
generation of ROS (Thakor et al., 2017). Furthermore, PYT caused activation of TRAIL, TNF-α 
receptors, and FAS, along with caspase-9 and -3 activation, and displayed a good binding 
affinity to glucose-6-phosphate dehydrogenase (G6PD), an enzyme which is known to promote 
tumor proliferation. Based on these findings, it was concluded that PYT has the potential as a 
drug candidate for counteracting lung carcinoma. 
 
ANTIOXIDANT ACTION  
Low concentrations of diverse EOs are well-known to possess antioxidant potentials 
(Bakkali et al., 2008; Islam et al., 2015). They are able to scavenge reactive oxygen and/or 
nitrogen species (ROS/RNS) produced by cellular stress and metabolism (Bakkali et al., 2008). 
Antioxidants act through three possible mechanisms: i) direct scavenging of reactive species via 
electron capturing and hydrogen radical transfer, ii) neutralization through redox reactions, and 
iii) oxidizing substrates. In this context, low concentrations of diverse EOs have proven to be 
beneficial, however, at high concentrations, the release of hydrogen radicals (H•) from active 
phenolic sites leaves phenoxy radicals (PhO•), which can eventually cause oxidation, thus 
leading to an antioxidant-induced oxidative effect. Therefore, phenolic antioxidants can also act 
as pro-oxidants causing cytogenotoxic effects. Several publications indicated that PYT has a 
potential for antioxidant activity (Pejin et al., 2014b; Santos et al., 2013). On the other hand, 
numerous studies revealed that EOs do not induce genetic mutations. They can, however, prevent 
the action of mutagens, by (i) inactivating them by direct scavenging, capturing radicals 
produced by mutagens, and (ii) activating enzymatic detoxification systems (Bakkali et al., 
2008). Furthermore, antioxidants with prooxidative activity can increase the levels of 
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malondialdehyde (MDA), which is an important genotoxic agent (Bakkali et al., 2008). It is well 
known that ROS may cause DNA damage. One type of ROS is the hydroxyl radical (•OH), 
which has the potential to generate single strand breaks (SSB) in DNA (Sage and Harrison, 
2011). Therefore, the PYT hydroxyl radical scavenging capacity may prevent such types of 
events of DNA damage (Pejin et al., 2014b).  
The double bond in phytol is not a good candidate for acting as a free radical scavenger due 
to the absence of conjugation (what we usually see in case of our dietary conjugated double bond 
containing fatty acids). However, free radicals can be scavenged by the hydrogen of the alcohol 
group, and the double bond can help in producing resonance structure of the stable free radical 
(Islam et al., 2016a). There is one study to suggest that two different mechanisms are the base of 
getting twice the antioxidant effect of phytol in lipid medium than in aqueous medium in the lab 
experiments (Islam et al., 2016a). While in general saturated aliphatic alcohols are not good 
antioxidants, phytol exhibits a good antioxidant activity because of the allylic nature of the 
alcohol group. For the proposed one mechanism, there might be indeed some involvement of the 
double bond in the formation of an intermediate resonance structure where the oxygen can form 
a double bond with the adjacent carbon while the double bond shifts to 3,4 carbon (Islam et al., 
2016a). 
PA is a carboxylic acid, and therefore it may undergo oxidative decarboxylation. Enzymes 
involved in such reactions are known as decarboxylases. More explicitly, oxidative 
decarboxylations are reactions in which a carboxylate group is removed, resulting in the 
formation of carbon dioxide. These reactions are often found in biological systems, for example 
as a part of the citric acid cycle. Thus far, two variations of the free radical reactions of 
carboxylic acids (RO2• + RiCOOH → ROOH + RiCO2• and ROi• + RjCOOH → ROOH + Ri• + 
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CO2) have been analyzed theoretically (Denisov and Shestakov, 2013). The cytotoxic activity of 
PA may be linked to overproduction of free radicals under specific conditions. In this context, 
PA concentration between 1 and 500 µM was shown to cause oxidative damage of cerebellum 
and cerebral cortex of Wistar male rats (Leipnitz et al., 2010).  
Some of the bioactivities of PYT which could be related to its redox properties are its 
reported in vitro anticancer effects (Chikati, 2013; Guo et al., 2014; Hibasami et al., 2002; Kim 
et al., 2015; Komiya et al., 1999), anti-teratogenic activity (Arnhold et al., 2002), tumor-
promotor (Kagoura et al., 1999) and anti-tumor activity (Líška et al., 2011). Depicted in Figure 3 
are proposed PYT-mediated antioxidant mechanisms (Islam et al., 2016b).  
 
INDUCTION OF APOPTOSIS AND PROTECTIVE AUTOPHAGY 
PYT can induce both apoptosis and protective autophagy. However, the molecular 
mechanisms of the cytotoxic effects of PYT in cancer cells remain poorly understood. Song and 
coworkers have shown that PYT stimulates both apoptosis and autophagy in human gastric 
adenocarcinoma AGS cells. PYT, when incubated with cells, induced accumulation of acidic 
vesicle, and downregulated protein kinase B (Akt), mTOR (mechanistic target of rapamycin), 
and p70S6K phosphorylation. Notably, pre-incubation with chloroquine, a lysosomal inhibitor, 
increased PYT-stimulated apoptosis in AGS cells, which suggests that PYT might stimulate a 
protective autophagy. In addition, co-incubation with a ROS scavenger increased the PYT-
stimulated cytotoxicity. These results may provide the foundation of novel insights into possible 
treatments of cancer using PYT (Song and Cho, 2015). Shown in Figure 4 are apoptosis- and 
autophagy-modulating effects of PYT. 
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In a similar fashion, Thakor and coworkers also have demonstrated that PYT, isolated 
from Abutilon indicum leaves, decreases the viability (42%, applied at 0.37 µM) and showed 
different phases of ROS-mediated programmed cell death in AO-EtBr stained 
Schizosaccharomyces pombe (fission yeast) cells. These researchers concluded that this 
investigation could be extended to an in vitro cancer study using different cell lines, and could 
open the door to find the exact mechanism of action of phytol as a potential candidate for the 
treatment of malignant neoplastic disease (Thakor et al., 2016). 
 
ANXIOLYTIC AND ANTICONVULSANT EFFECTS  
Anxiety is a kind of mental condition which often results from a trauma. In some cases, anxiety 
can be accompanied by a depressive mood (Hunt et al., 2003; Vieweg et al., 2006). In general, 
anxiety disorders are a group of mental conditions which can be triggered by genetic 
predispositions, drugs, and withdrawal from certain drugs. Medications and change of lifestyle 
are common approaches in the treatment of anxiety. Benzodiazepines (BDZ) are the first-line of 
drugs that have been prescribed for patients with anxiety for over four decades (Starcevic, 2014). 
Diazepam, the most commonly prescribed BDZ used in the treatment of anxiety, is a positive 
allosteric modulator of γ-aminobutyric acid type A receptors (GABAA). GABAA receptor is a 
ligand-gated chloride-selective ion channel that is activated by GABA, an inhibitory 
neurotransmitter in the brain (Griffin et al., 2013). Binding of BDZ to this receptor complex 
potentiates the binding of GABA, which ultimately enhances the total movement of chloride ions 
(Cl-) across the neuronal cell membrane. This enhanced Cl--influx hyperpolarizes the neuron's 
membrane and reduces the chance of action potential to occur (inhibition of neurotransmission). 
GABAA receptors containing the α1 subunit mediate the sedative, and in part the anticonvulsive 
effects of diazepam, whereas the anxiolytic action of diazepam is mediated by the GABAA 
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receptors containing α2 subunit (Tan et al., 2014).  Phytol is recognized for its wide range of 
pharmacological effects on the nervous system, including anxiolytic and antidepressant (Pereira 
Costa et al., 2014). Common neuropsychological disorders, such as anxiety, epilepsy and 
depression are related and coexist in some patients. The lifetime prevalence of epilepsy in 
association with depression was approximated to be as high as 55% (Jackson and Turkington, 
2005). Yet remarkably lesser information exists on the mechanism of depression and anxiety in 
convulsion and its treatments. 
In this context, the anticonvulsant effect of PYT has been also demonstrated (Costa et al., 
2012). Recent work conducted by Costa et al. on Swiss albino mice (Costa et al., 2014) has found 
that PYT (25, 50, or 75 mg/kg by intraperitoneal injection, i.p.) also displays anti-anxiety 
activity. By inducing anxiolytic effects, BDZ drugs such as diazepam increase inhibitory 
processes in the cerebral cortex (Zakusov et al., 1977). Hoffmann-La Roche has first introduced 
another drug, flumazenil, a GABAA receptor antagonist, in 1987. It was primarily used to treat 
BDZ overdoses and to help reverse anesthesia (Rye et al., 2012). Bang and colleagues (Bang et 
al., 2002) suggested that PYT is able to bring the elevated levels of neurotransmitter GABA to 
optimal levels in the central nervous system. As previously mentioned, diazepam exerts both of 
its anxiolytic and anticonvulsant effects through GABAA receptor subunits α1 and α2, 
respectively. On the other hand, the antagonizing influence of flumazenil against both types of 
PYT effects, show that both flumazenil and PYT may exert their CNS effects by targeting the α1 
and α2 GABAA receptor subunits (Costa et al., 2014; Costa et al., 2012). However, further 
research is needed to gain deeper understanding about the anxiolytic and anticonvulsant activities 
of PYT.  
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IMMUNE-MODULATING PROPERTIES 
Several recent studies have suggested that some PYT-derivatives (phytanol, phytanyl amine, 
and phytanyl mannose) exert immune-stimulating activity by induction of the expression of a 
range of chemokines and cytokines (Aachoui et al., 2011a; Roy Chowdhury et al., 2013) and  
modulation of immune responses through apoptotic/necrotic (Aachoui et al., 2011b) effects on 
target tumor cells. 
The immune system relies on production of chemically reactive molecules such as reactive 
oxygen and reactive nitrogen species (ROS/RNS), along with phagocytosis; these reactive 
intermediates can damage DNA and other molecules, and facilitates the neutralization of 
pathogens (Nathan and Shiloh, 2000). However, this is an example of short-term, rather than 
long-term oxidative stress, since the later causes cytotoxicity and genotoxicity, which may 
damage or kill the phagocytes as well as other host cells (Rice-Evans and Gopinathan, 1995). 
Nakanishi et al. (2016) have recently observed that PA, PYT, and pristanic acid (3, 10, and 30 
µM) cause substantial reduction of interferon-gamma (IFN-γ), interleukin (IL)-4, and -10 
production in mouse splenocytes stimulated by T-cell mitogens (Nakanishi et al., 2016). 
Additionally, PA and PYT inhibit production of IL-17A production, which overall suggests a 
potentially beneficial effect for the amelioration of T-cell mediated autoimmune diseases. 
 
ANTINOCICEPTIVE AND ANTI-INFLAMMATORY ACTIVITY OF PYT 
Nociception is defined as the process of encoding and processing of noxious stimuli by the 
nervous system (Loeser and Treede, 2008). Substances capable of modulating the responsible 
signaling pathways can be employed to control the intensity of pain which can be a vital signal 
for inflammation. Inflammation is the complex biological response of vascularized tissues to 
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harmful stimuli (e.g., pathogens, damaged cells, or irritants), involving the local formation of 
kinins and cytokines, that promote activation of vascular endothelial cells, followed by migration 
of leukocytes into the inflamed site. Production of oxidative mediators is another response to 
inflammation (Medzhitov, 2008; Silva et al., 2014). In this context, pain is an indispensable 
signal for inflammation. Degree of inflammation is a very important factor since minor localized 
and tightly controlled inflammation is usually beneficial for defensive purposes. However, 
chronic inflammation may lead to diverse diseases, such as atherosclerosis, rheumatoid arthritis, 
pain, and cancer, among others. Therefore, anti-inflammatory agents may be considered as 
preventive or therapeutic depending on the context.  
The antinociceptive (Santos et al., 2013) and anti-inflammatory (Silva et al., 2014) activities 
of PYT may be interrelated. Recent data from Swiss mice treated with PYT (i.p.) showed a 
potent dose-dependent (applied at 25, 50, 100, and 200 mg/kg) antinociceptive response in hot-
plate or chemical-induced (acetic acid, formaldehyde) nociceptive tests when compared to those 
treated with 10 mg/kg of the reference compounds morphine and indomethacin (i.p.). Taken 
together, these results demonstrate that PYT could be a potential therapeutic approach in 
different contexts. Additionally, anti-inflammatory tests performed by Silva et al.(2014) 
indicated that PYT attenuates the inflammatory response by inhibiting neutrophil migration, 
which is partly caused by reduction in tumor necrosis factor-alpha (TNF-α) and IL-1β levels 
(Silva et al., 2014). These findings suggest that the antioxidant, anti-inflammatory, and 
antinociception activities of PYT may be connected to each other. Additionally, these results 
show that PYT could be a good candidate to be further evaluated for other relevant bioactivities, 
such as for antipyretic, antiperiodontitis, and anti-arthritic activities. 
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PYT IN METABOLIC DISORDERS AND EFFECTS RELATED TO PPARS 
Peroxisome proliferator-activated receptors (PPARs) are a subfamily of the nuclear 
receptor superfamily involved in a multitude of cellular mechanisms (Dreyer et al., 1992). 
PPARs can be further classified as α, β/δ, or γ, the latter being further divided into γ1, γ2, and γ3.  
PPARα is expressed in liver, kidney, heart, muscle, and adipose tissues (Tyagi et al., 2011), 
whereas PPARβ/δ is found in many tissues, specifically the brain, adipose tissues, and skin. The 
γ1 subunits are expressed in virtually all tissues, including the heart, muscle, colon, kidney, 
pancreas, and spleen, whereas the γ3 subunits are found in macrophages, the large intestine, and 
white adipose tissue. Finally, γ2 is mainly expressed in adipose tissue. These groups of nuclear 
receptor proteins are essential for the regulation of cellular differentiation, development, nutrient 
metabolism, and tumorigenesis (Belfiore et al., 2009) in higher organisms (Feige et al., 2006).  
Activity of PPARs depends on the precise shape of the ligand-binding domain (LBD), as 
well as on the number and type of coactivator and the presence of corepressor proteins (Yu and 
Reddy, 2007). Free fatty acids and eicosanoids are believed to be endogenous ligands of the 
PPARs. It is important to emphasize that eicosanoid PPAR ligands are important regulators of 
inflammatory responses, and that overall PPAR signaling is known to modulate inflammation. In 
this context, there are experimental data suggesting a link between PPAR modulation and the 
observed anti-inflammatory activity of PYT (Silva et al., 2014).  
PPARγ is an important regulator of genes that affect insulin action. A tumor necrosis 
factor-alpha (TNF-α), a pro-inflammatory cytokine, which is associated with insulin resistance 
and decreased insulin signal transduction (Berger and Moller, 2002). Therefore, the TNF-α 
inhibitory activity observed by Silva and coworkers may indicate not only anti-inflammatory but 
also a potential anti-diabetic activity of PYT. Moreover, there are recognized PPARγ ligands, 
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such as rosiglitazone, that exert anti-inflammatory effects by inhibiting the activation of the NF-
κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway (Zhang et al., 2016). 
NF-κB, a protein complex that controls DNA transcription, cytokine production, and cell 
survival, is found in almost all eukaryotic cell types (Brasier, 2006; Gilmore, 2006; Perkins, 
2007). It is involved in cellular responses to a number of stimuli, such as stress, cytokines, free 
radicals, ultraviolet irradiation, oxidized low-density lipoprotein (LDL), and pathogens. It 
additionally plays a key role in regulating the immune response. Abnormality in its regulation 
has been linked to cancer, inflammatory and autoimmune diseases, viral infection, and improper 
immune development (Levenson et al., 2004; Perkins, 2007). In several studies, PPARγ 
expression has also been implied in a variety of cancer cells, including human mammary 
adenocarcinomas and colon cancer cells (Berger and Moller, 2002). Thus, the anticancer and 
immune adjuvant activities of PYT and its derivatives may be linked to potential effects on both 
PPARs and NF-κB. In this regard, there has also been reported evidence of PYT acting as an 
anti-scratching compound when applied in 5 and 10 mg/kg (dissolved in 5% cremophor; p.o.) in 
male ICR and BALB/c mice by inhibiting allergic cytokines expression through regulation of 
NF-κB and activator protein (AP)-1 (Ryu et al., 2011).   
Research by Matsuda et al. (2013) showed that PYT, applied as PPARα ligand, increases 
blood NAD level by suppressing hepatic alpha-amino-beta-carboxymuconate-epsilon-
semialdehyde decarboxylase (ACMSD) mRNA expression in the rat´s liver (Matsuda et al., 
2013). In addition, a PPARα-mediated activity of PYT has been investigated by a number of 
other research groups. Mackie et al. (2009) showed that PYT (0.5 and 1.0%; p.o.) causes 
consistent PPARα-mediated responses such as lower body weight, higher liver weights, 
hepatocellular hypertrophy, peroxisome proliferation, and enhanced catalase expression in mice. 
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PYT additionally causes female mice-specific hepatotoxicity, which was explained by the lower 
hepatic expression of sterol carrier protein-x (SCP-x), linked to a lower capacity to oxidize PA. 
Based on the preceding discussion, it is evident that PPARα can play an important role in the 
induction of hepatomegaly and hepatocarcinogenesis in rodents, as well as in the expression of 
the fatty acid transport protein (FATP) (Berger and Moller, 2002). Thus, the hepatotoxic activity 
of PYT may be PPARα-dependent. However, how exactly the activity of PTY is associated with 
hepatotoxicity remains still not entirely clear and more research is needed to address the 
mechanisms underlying this bioactivity.  
Hypertension is a disorder of the cardiovascular system that is often linked to insulin 
resistance and obesity. People with type-2-diabetes (T2D) are 1.5 to 2-fold more likely to 
develop hypertension than the rest of the population (Berger and Moller, 2002). PYT (250 
mg/kg) showed modulatory effects in the RXR ligand and PPARγ to diabetic insulin-resistant 
rats. PYT docking on the RXRα/PPARγ heterodimer revealed that it has a  higher binding 
affinity and a lesser energy score on RXRα under diabetic conditions (Elmazar et al., 2013). 
These findings suggest that the insulin sensitizing/anti-diabetic effect of PYT is mediated partly 
by activation of nuclear receptors and heterodimerization of RXR with PPARγ by phytanic acid. 
In addition, since PPAR responses and hypertension are related to T2D, it might be of interest to 
evaluate PYT as a potential antihypertensive agent. On the other hand, T2D is often associated 
with weight gain, high blood pressure, and increased pro-inflammatory cytokines, which are all 
linked to insulin resistance. In the context of metabolic disorders, research findings showed that 
PYT has cholesterol-lowering (Olofsson et al., 2010) potentials in mice. Furthermore, 
atherosclerosis has a strong association with elevated LDL-cholesterol as well as with diabetes, 
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therefore, PYT could be considered as a promising candidate to be further examined for possible 
anti-atherosclerotic action.  
Adipogenesis is a key process regulating metabolic health, and PPARγ is a key regulator 
of adipogenesis. Wang and coworkers demonstrated that PYT administration increases adipocyte 
number in inguinal subcutaneous white adipose tissue and improves glucose tolerance in mice 
fed with high-fat and high fructose diet. This was consistent with the enhanced adipogenesis and 
glucose uptake in 3T3-L1 cell line, and was associated with activation of phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K)/Akt signaling pathway (Wang et al., 2017). In addition, PYT 
administration in mice caused increased expression of marker genes associated with 
adipogenesis (C/EBPα and PPARγ) in inguinal subcutaneous white adipose tissue. These data 
provided new insights into the regulation of adipogenesis and glucose uptake by dietary PYT and 
suggested the application of PYT as a potential nutritional agent to combat obesity and type 2 
diabetes (Wang et al., 2017). Shown in Table 1 and 2 is a summary of PYT bioactivity studies. 
In human glioblastoma cell lines (U87MG, A172, and T98G), PYT and retinol showed 
dose-dependent cytotoxicity and downregulated genes involved in cholesterol or fatty acid 
biosynthetic pathways (Facchini et al., 2018). In particular, PYT suppressed the expression levels 
of sterol regulatory element-binding protein 1 (SREBP-1) together with its downstream target 
protein fatty acid synthase (FAS). PYT was also associated with suppression of farnesyl-
diphosphate farnesyltransferase (FDFT1) which regulates cholesterol synthesis (Facchini et al., 
2018). These observations suggest that PYT may have the potential to be used as an agent to 
regulate cholesterol biosynthesis, and thus may have possible therapeutic applications in 
preventing or treating hyperlipidemia conditions, as an approach to combat cardiac diseases. 
PYT was also shown to regulate adipocytes phenotype, which might have implications for 
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counteracting obesity and related cardiovascular and metabolic disorders. In this line, PYT 
administration suppressed body weight gain and inguinal subcutaneous white adipose tissue 
index, whereby stimulating the expression of brown adipocyte marker genes, including UCP1, 
PGC1α, PRDM16, PDH, and Cytochrome C (Zhang et al., 2018).  
In addition, PYT activated the AMPKα signaling in mice and stimulated brown-
adipogenic differentiation of 3T3-L1 cells by increasing the mitochondria content and 
stimulating oxygen consumption (Zhang et al., 2018). Obesity-regulating effects of PYT was 
further studied by An et al. (2018). These authors observed that a PYT-enriched diet may 
increase PA levels in the liver and brown adipocytes. In this way, dietary PYT may activate 
PPARα in liver, resulting in amelioration of obesity-induced metabolic diseases. In a similar 
fashion, Wang et al. (2018) reported that PYT can regulate hyperplasia/adipogenesis and glucose 
homeostasis in high-fat and high fructose diet (HFFD) in mice. These researchers found that 
PYT decreases body weight gain and inguinal subcutaneous white adipose tissue weight. 
Moreover, PYT improved the OGTT glucose tolerance in mice and activated marker genes 
associated with adipogenesis (C/EBPα and PPARγ) and glucose uptake (GLUT4 and AS160), 
and activated the PI3K/Akt signal transduction pathway (Wang et al., 2018). On the other hand, 
Mezzar and colleagues have recently investigated phytol-induced pathology in 2-hydroxyacyl-
CoA lyase (HACL1) deficient mice (Mezzar et al., 2017). HACL1 is a major enzyme of the 
peroxisomal α-oxidation of PA. Results showed that accumulation of the PYT metabolite PA in 
liver tissues and serum in the KO mice was associated with a significant weight loss, absence of 
abdominal white adipose tissue, anatomical changes of the liver, and decreased hepatic glycogen 
and triglyceride content (Mezzar et al., 2017). 
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RECENT MISCELLANEOUS APPLICATIONS 
PYT and its derivatives have also shown other interesting bioactivities. Apart from the 
pharmacological effects in disease management, PYT was reported to display a potential in 
counteracting hyperpigmentation, with a possible application as a skin whitening agent in 
cosmetics (Ko and Cho, 2018). Ko and Cho have recently employed B16F10 murine melanoma 
cells, to demonstrate that PYT can inhibit α-melanocyte-stimulating hormone-induced 
melanogenesis, in association with suppressed expression of tyrosinase and tyrosinase-related 
protein 1 (Ko and Cho, 2018).  
Bioavailability of PYT could represent a barrier for its potential therapeutic applications, 
and the use of nanocarriers-mediated delivery systems might be a possible solution. Sathya et al. 
(2017) recently showed that PYT loaded on poly(lactic-co-glycolic acid) (PLGA) nanoparticles 
may enhance cellular uptake of the compound and thus might result in higher effectiveness when 
tested in vitro in a cellular model with a relevance for Alzheimer's disease. These authors also 
demonstrated that PYT is released in vitro in a sustained manner, and that treatment with PYT-
loaded nanoparticles led to disruption of amyloid aggregates and resulted in anti-cholinesterase 
and anti-oxidative action, without signs of toxicity in Neuro2a cells (Sathya et al., 2018). In 
another work, a nanoemulsion of PYT was prepared and delivered in Artemia salina and Allium 
cepa for toxicity, cytotoxicity, and genotoxicity analysis (Islam et al., 2017). Results revealed 
that PYT-nanoemulsion has enhanced effects as compared to PYT, and that the studied PYT-
nanoemulsion formulation has an improved bioavailability (Islam et al., 2017).  
Finally, a very interesting aspect associated with PYT application is related to interaction 
with gut microbiota, which plays important roles in diverse metabolic processes and human 
diseases such as obesity, diabetes, fatty liver disease, and cardiovascular diseases. In this context, 
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food constituents such as PYT might have a variety of health and disease-related effects that 
might be associated with effect on the human gut microbiota (Roca-Saavedra et al., 2018). PA is, 
for example, known to get oxidized by the rumenal microbiota of certain marine organisms 
(Roca-Saavedra et al., 2017).  
 
CONCLUSIONS 
Phytol and its derivatives exhibit a wide range of bioactivities including antianxiety, 
cytotoxic, metabolism-modulating, antioxidant, autophagy- and apoptosis-inducing, anti-
nociceptive, anti-inflammatory, immune-modulating, and antimicrobial effects. Abundance of 
PYT in nature and its diverse bioactivities make it a commercially important compound. 
Although PPARs- and NF-κB-mediated activities have been pointed out as responsible for some 
of the bioactivities of PYT, further studies are needed to address more thoroughly the molecular 
mechanisms of action of PYT and its derivatives. 
 
ACKNOWLEDGEMENTS 
AGA acknowledges the support by the Polish KNOW (Leading National Research Centre) 
Scientific Consortium “Healthy Animal—Safe Food,” decision of Ministry of Science and 
Higher Education No. 05-1/KNOW2/2015. 
 
AUTHOR CONTRIBUTIONS 
MTI, ESA, JAS, and AGA have written the first draft of the manuscript. All other authors have 
revised and improved the first draft. All authors have seen and agreed on the finally submitted 
version of the manuscript. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
CONFLICTS OF INTEREST 
Authors declare no conflict of interest. 
 
REFERENCES 
Aachoui, Y., Chowdhury, R.R., Fitch, R.W., Ghosh, S.K., 2011a. Molecular signatures of phytol-derived 
immunostimulants in the context of chemokine–cytokine microenvironment and enhanced immune response. 
Cellular Immunology 271, 227-238. 
Aachoui, Y., Schulte, M.L., Fitch, R.W., Ghosh, S.K., 2011b. Synthetic adjuvants for vaccine formulations: 
Evaluation of new phytol derivatives in induction and persistence of specific immune response. Cellular 
Immunology 271, 308-318. 
Arnhold, T., Elmazar, M.M.A., Nau, H., 2002. Prevention of Vitamin A Teratogenesis by Phytol or Phytanic Acid 
Results from Reduced Metabolism of Retinol to the Teratogenic Metabolite, All-trans-retinoic Acid. Toxicological 
Sciences 66, 274-282. 
Bakkali, F., Averbeck, S., Averbeck, D., Idaomar, M., 2008. Biological effects of essential oils – A review. Food 
and Chemical Toxicology 46, 446-475. 
Bang, M., Choi, S., Jang, T., Kim, S., Kwon, O., Kang, T., 2002. Phytol, SSADH inhibitory diterpenoid of Lactuca 
sativa. Arch Pharm Res. 25, 643-646. 
Belfiore, A., Genua, M., Malaguarnera, R., 2009. PPAR-γ Agonists and Their Effects on IGF-I Receptor Signaling: 
Implications for Cancer. PPAR Research 2009, 830501. 
Berger, J., Moller, D., 2002. The Mechanisms of Action of PPARs. Annual Review of Medicine 53, 409-435. 
Borges, C.G., Canani, C.R., Fernandes, C.G., Zanatta, Â., Seminotti, B., Ribeiro, C.A.J., Leipnitz, G., Vargas, C.R., 
Wajner, M., 2015. Reactive nitrogen species mediate oxidative stress and astrogliosis provoked by in vivo 
administration of phytanic acid in cerebellum of adolescent rats: A potential contributing pathomechanism of 
cerebellar injury in peroxisomal disorders. Neuroscience 304, 122-132. 
Brasier, A.R., 2006. The NF-kappaB regulatory network. Cardiovascular toxicology 6, 111-130. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
Chikati, R., 2013. Molecular Evaluation of RNase from Aspergillus niger and Phytol of Nymphaea pubescens as 
Cytoskeletol targeting elements in Cancer. Epidemiology, (Aug:21-23); Holiday Inn, Ornaldo-Fl, USA. 
Costa, J.P., de Oliveira, G.A.L., de Almeida, A.A.C., Islam, M.T., de Sousa, D.P., de Freitas, R.M., 2014. 
Anxiolytic-like effects of phytol: Possible involvement of GABAergic transmission. Brain Research 1547, 34-42. 
Costa, J.P., Ferreira, P.B., De Sousa, D.P., Jordan, J., Freitas, R.M., 2012. Anticonvulsant effect of phytol in a 
pilocarpine model in mice. Neuroscience Letters 523, 115-118. 
da Silva, J.M., Antinarelli, L.M.R., Ribeiro, A., Coimbra, E.S., Scio, E., 2015. The effect of the phytol-rich fraction 
from Lacistema pubescens against Leishmania amazonensis is mediated by mitochondrial dysfunction. 
Experimental Parasitology 159, 143-150. 
de Moraes, J., de Oliveira, R.N., Costa, J.P., Junior, A.L.G., de Sousa, D.P., Freitas, R.M., Allegretti, S.M., Pinto, 
P.L.S., 2014. Phytol, a Diterpene Alcohol from Chlorophyll, as a Drug against Neglected Tropical Disease 
Schistosomiasis Mansoni. PLOS Neglected Tropical Diseases 8, e2617. 
de Souza, N.J., Nes, W.R., 1969. The presence of phytol in brown and blue-green algae and its relationship to 
evolution. Phytochemistry 8, 819-822. 
Denisov, E.T., Shestakov, A.F., 2013. Free-radical decarboxylation of carboxylic acids as a concerted abstraction 
and fragmentation reaction. Kinetics and Catalysis 54, 22-33. 
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., Wahli, W., 1992. Control of the peroxisomal &#x3b2;-
oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-887. 
Elmazar, M.M., El-Abhar, H.S., Schaalan, M.F., Farag, N.A., 2013. Phytol/Phytanic Acid and Insulin Resistance: 
Potential Role of Phytanic Acid Proven by Docking Simulation and Modulation of Biochemical Alterations. PLOS 
ONE 8, e45638. 
Faix, Š., Juhas, Š., Faixová, Z., 2007. The Effect of Essential Oil Intake on Changes of Plasma Antioxidant Status in 
Mice. Acta Vet. Brno 76, 357-361. 
Feige, J.N., Gelman, L., Michalik, L., Desvergne, B., Wahli, W., 2006. From molecular action to physiological 
outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. 
Progress in Lipid Research 45, 120-159. 
Ghaneian, M.T., Ehrampoush, M.H., Jebali, A., Hekmatimoghaddam, S., Mahmoudi, M., 2015. Antimicrobial 
activity, toxicity and stability of phytol as a novel 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
surface disinfectant. Environmental Health Engineering and Management Journal 2, 13-16. 
Gilmore, T.D., 2006. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25, 6680-6684. 
Gloerich, J., Ruiter, J.P.N., van den Brink, D.M., Ofman, R., Ferdinandusse, S., Wanders, R.J.A., 2006. Peroxisomal 
trans-2-enoyl-CoA reductase is involved in phytol degradation. FEBS Letters 580, 2092-2096. 
Gloerich, J., van den Brink, D.M., Ruiter, J.P., van Vlies, N., Vaz, F.M., Wanders, R.J., Ferdinandusse, S., 2007. 
Metabolism of phytol to phytanic acid in the mouse, and the role of PPARalpha in its regulation. Journal of lipid 
research 48, 77-85. 
Griffin, C.E., 3rd, Kaye, A.M., Bueno, F.R., Kaye, A.D., 2013. Benzodiazepine pharmacology and central nervous 
system-mediated effects. Ochsner J 13, 214-223. 
Guo, J., Yuan, Y., Lu, D., Du, B., Xiong, L., Shi, J., Yang, L., Liu, W., Yuan, X., Zhang, G., Wang, F., 2014. Two 
natural products, trans-phytol and (22E)-ergosta-6,9,22-triene-3β,5α,8α-triol, inhibit the biosynthesis of estrogen in 
human ovarian granulosa cells by aromatase (CYP19). Toxicology and Applied Pharmacology 279, 23-32. 
Hibasami, H., Kyohkon, M., Owaki, S., Katsuzaki, H., Imai, K., Ohnishi, K., 2002. Diol- and triol-types of phytol 
induce apoptosis in lymphoid leukemia Molt 4B cells. International Journal of Molecular Medicine 10, 555-559. 
Hunt, M., Auriemma, J., Cashaw, A.C.A., 2003. Self-Report Bias and Underreporting of Depression on the BDI-II. 
Journal of Personality Assessment 80, 26-30. 
Inoue, Y., Hada, T., Shiraishi, A., Hirose, K., Hamashima, H., Kobayashi, S., 2005. Biphasic Effects of 
Geranylgeraniol, Teprenone, and Phytol on the Growth of Staphylococcus aureus. Antimicrobial Agents and 
Chemotherapy 49, 1770-1774. 
Ischebeck, T., Zbierzak, A.M., Kanwischer, M., Dörmann, P., 2006. A Salvage Pathway for Phytol Metabolism in 
Arabidopsis. Journal of Biological Chemistry 281, 2470-2477. 
Islam, M.T., de Alencar, M.V.O.B., da Conceição Machado, K., da Conceição Machado, K., de Carvalho Melo-
Cavalcante, A.A., de Sousa, D.P., de Freitas, R.M., 2015. Phytol in a pharma-medico-stance. Chemico-Biological 
Interactions 240, 60-73. 
Islam, M.T., Streck, L., Correia Jardim Paz, M.F., de Castro e Sousa, J.M., Alencar, M.V.O.B.d., Oliveira Ferreira 
da Mata, A.M., Melo de Carvalho, R., de Oliveira Santos, J.V., da Silva-Junior, A.A., Pinheiro Ferreira, P.M., de 
Carvalho Melo-Cavalcante, A.A., 2016a. Preparation of Phytol-Loaded Nanoemulsion and Screening for 
Antioxidant Capacity. International Archives of Medicine 9. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
24 
Islam, M.T., Streck, L., Paz, M.F.C.J., e Sousa, J.M.d.C., de Alencar, M.V.O.B., Maria, A., da Mata, O.F., da Silva, 
M.B.S., de Carvalho, R.M., 2016b. Preparation of phytol-loaded nanoemulsion and screening for antioxidant 
capacity: data-in-brief. International Archives Of Medicine 9. 
Jackson, M.J., Turkington, D., 2005. Depression and anxiety in epilepsy. J Neurol Neurosurg Psychiatry 76 Suppl 1, 
i45-47. 
Kagoura, M., Matsui, C., Morohashi, M., 1999. Phytol Is a Novel Tumor Promoter on ICR Mouse Skin. Japanese 
Journal of Cancer Research 90, 377-384. 
Kim, C.-W., Lee, H.J., Jung, J.H., Kim, Y.H., Jung, D.-B., Sohn, E.J., Lee, J.H., Woo, H.J., Baek, N.-I., Kim, Y.C., 
Kim, S.-H., 2015. Activation of Caspase-9/3 and Inhibition of Epithelial Mesenchymal Transition are Critically 
Involved in Antitumor Effect of Phytol in Hepatocellular Carcinoma Cells. Phytotherapy Research 29, 1026-1031. 
Komiya, T., Kyohkon, M., Ohwaki, S., Eto, J., Katsuzaki, H., Imai, K., 1999. Phytol induces programmed cell death 
in human lymphoid leukemia Molt 4B cells. International Journal of Molecular Medicine 4, 377-380. 
Leipnitz, G., Amaral, A.U., Zanatta, Â., Seminotti, B., Fernandes, C.G., Knebel, L.A., Vargas, C.R., Wajner, M., 
2010. Neurochemical evidence that phytanic acid induces oxidative damage and reduces the antioxidant defenses in 
cerebellum and cerebral cortex of rats. Life Sciences 87, 275-280. 
Levenson, J.M., Choi, S., Lee, S.-Y., Cao, Y.A., Ahn, H.J., Worley, K.C., Pizzi, M., Liou, H.-C., Sweatt, J.D., 2004. 
A Bioinformatics Analysis of Memory Consolidation Reveals Involvement of the Transcription Factor c-Rel. The 
Journal of Neuroscience 24, 3933. 
Líška, J., Ondková, S., Macejová, D., Brtko, J., 2011. Histological evaluation of rat mammary tumours after 
treatment with retinoic acid analogues — phytol, TTNPB and vitamin D3 analogue seocalcitol. Biologia 66, 365-
369. 
Loeser, J.D., Treede, R.-D., 2008. The Kyoto protocol of IASP Basic Pain Terminology☆. PAIN 137, 473-477. 
Mackie, J.T., Atshaves, B.P., Payne, H.R., McIntosh, A.L., Schroeder, F., Kier, A.B., 2009. Phytol induced 
hepatotoxicity in mice. Toxicologic pathology 37, 201-208. 
Matsuda, H., Gomi, R.-t., Hirai, S., Egashira, Y., 2013. Effect of Dietary Phytol on the Expression of α-Amino-β-
carboxymuconate-ε-semialdehyde Decarboxylase, a Key Enzyme of Tryptophan-niacin Metabolism, in Rats. 
Bioscience, Biotechnology, and Biochemistry 77, 1416-1419. 
Medzhitov, R., 2008. Origin and physiological roles of inflammation. Nature 454, 428-435. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
25 
Murbach Teles Andrade, B.F., Nunes Barbosa, L., da Silva Probst, I., Fernandes Júnior, A., 2014. Antimicrobial 
activity of essential oils. Journal of Essential Oil Research 26, 34-40. 
Nagai, K., 2015. Phytanic acid induces Neuro2a cell death via histone deacetylase activation and mitochondrial 
dysfunction. Neurotoxicology and Teratology 48, 33-39. 
Nakanishi, T., Anraku, M., Suzuki, R., Kono, T., Erickson, L., Kawahara, S., 2016. Novel immunomodulatory 
effects of phytanic acid and its related substances in mice. Journal of Functional Foods 21, 283-289. 
Nathan, C., Shiloh, M., 2000. Reactive oxygen and nitrogen intermediates in the relationship between mammalian 
hosts and microbial pathogens. Proc Natl Acad Sci. USA 97, 8841-8848. 
Olofsson, P., Hultqvist, M., Holmdahl, R., 2010. Phytol as a cholesterol lowering agent. US Patents, 
2011,0015,278,. 
Pejin, B., Ciric, A., Glamoclija, J., Nikolic, M., Sokovic, M., 2015. In vitro anti-quorum sensing activity of phytol. 
Natural Product Research 29, 374-377. 
Pejin, B., Kartali, T., Stanimirovic, B., Karaman, M., 2014a. Phytol May Inspire New Medicinal Foods for the 
Treatment of Heart Disease. Asian. J. Chem. 26, 8261-8262. 
Pejin, B., Savic, A., Sokovic, M., Glamoclija, J., Ciric, A., Nikolic, M., Radotic, K., Mojovic, M., 2014b. Further in 
vitro evaluation of antiradical and antimicrobial activities of phytol. Natural Product Research 28, 372-376. 
Pereira Costa, J., da Silva Oliveira, J., Mario Rezende Junior, L., de Freitas, R.M., 2014. Phytol a Natural 
Diterpenoid with Pharmacological Applications on Central Nervous System: A Review. Recent Pat Biotechnol 8, 
194-205. 
Perkins, N.D., 2007. Integrating cell-signalling pathways with NF-[kappa]B and IKK function. Nat Rev Mol Cell 
Biol 8, 49-62. 
Prabuseenivasan, S., Jayakumar, M., Ignacimuthu, S., 2006. In vitro antibacterial activity of some plant essential 
oils. BMC Complementary and Alternative Medicine 6, 39-39. 
Proteau, P.J., 1998. Biosynthesis of Phytol in the Cyanobacterium Synechocystis sp. UTEX 2470:  Utilization of the 
Non-Mevalonate Pathway. Journal of Natural Products 61, 841-843. 
Rice-Evans, C., Gopinathan, V., 1995. Oxygen toxicity, free radicals and antioxidants in human disease: 
biochemical implications in atherosclerosis and the problems of premature neonates. Essays Biochem. 29, 39-63. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
26 
Rontani, J.-F., Volkman, J.K., 2003. Phytol degradation products as biogeochemical tracers in aquatic environments. 
Organic Geochemistry 34, 1-35. 
Roy Chowdhury, R., Fitch, R.W., Ghosh, S.K., 2013. Efficacy of phytol-derived diterpenoid immunoadjuvants over 
alum in shaping the murine host's immune response to Staphylococcus aureus. Vaccine 31, 1178-1186. 
Rye, D.B., Bliwise, D.L., Parker, K., Trotti, L.M., Saini, P., Fairley, J., Freeman, A., Garcia, P.S., Owens, M.J., 
Ritchie, J.C., Jenkins, A., 2012. Modulation of Vigilance in the Primary Hypersomnias by Endogenous 
Enhancement of GABA&lt;sub&gt;A&lt;/sub&gt; Receptors. Science Translational Medicine 4, 161ra151. 
Ryu, K.-R., Choi, J.-Y., Chung, S., Kim, D.-H., 2011. Anti-scratching Behavioral Effect of the Essential Oil and 
Phytol Isolated from Artemisia princeps Pamp. in Mice. Planta Medica 77, 22-26. 
Sage, E., Harrison, L., 2011. Clustered DNA lesion repair in eukaryotes: Relevance to mutagenesis and cell survival. 
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 711, 123-133. 
Saikia, D., Parihar, S., Chanda, D., Ojha, S., Kumar, J.K., Chanotiya, C.S., Shanker, K., Negi, A.S., 2010. 
Antitubercular potential of some semisynthetic analogues of phytol. Bioorganic & Medicinal Chemistry Letters 20, 
508-512. 
Santos, C.C.d.M.P., Salvadori, M.S., Mota, V.G., Costa, L.M., de Almeida, A.A.C., de Oliveira, G.A.L., Costa, J.P., 
de Sousa, D.P., de Freitas, R.M., de Almeida, R.N., 2013. Antinociceptive and Antioxidant Activities of Phytol In 
Vivo and In Vitro Models. Neuroscience Journal 2013, 9. 
Schönfeld, P., Reiser, G., 2006. Rotenone-like Action of the Branched-chain Phytanic Acid Induces Oxidative Stress 
in Mitochondria. Journal of Biological Chemistry 281, 7136-7142. 
Silva, R.O., Sousa, F.B.M., Damasceno, S.R.B., Carvalho, N.S., Silva, V.G., Oliveira, F.R.M.A., Sousa, D.P., 
Aragão, K.S., Barbosa, A.L.R., Freitas, R.M., Medeiros, J.V.R., 2014. Phytol, a diterpene alcohol, inhibits the 
inflammatory response by reducing cytokine production and oxidative stress. Fundamental & Clinical Pharmacology 
28, 455-464. 
Singh, R., Meena, A., Negi, A., Shanker, K., 2012. Quantitative relationships between molecular descriptors, 
chromatographic retention behavior, and in vitro antituberculosis activity of phytol derivatives. JPC - Journal of 
Planar Chromatography - Modern TLC 25, 10-18. 
Song, Y., Cho, S.K., 2015. Phytol Induces Apoptosis and ROS-Mediated Protective Autophagy in Human Gastric 
Adenocarcinoma AGS Cells. Biochem. Anal. Biochem.  4, 4-11. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
27 
Starcevic, V., 2014. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev 
Neurother 14, 1275-1286. 
Steinberg, D., Avigan, J., Mize, C.E., Baxter, J.H., Cammermeyer, J., Fales, H.M., Highet, P.F., 1966. Effects of 
dietary phytol and phytanic acid in animals. Journal of lipid research 7, 684-691. 
Tan, K., Rudolp, U., Lüscher, C., 2014. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. 
University of Geneva,  Retrieved December 12,. 
Thakor, P., Mehta, J.B., Patel, R.R., Patel, D.D., Subramanian, R.B., Thakkar, V.R., 2016. Extraction and 
purification of phytol from Abutilon indicum: cytotoxic and apoptotic activity. RSC Advances 6, 48336-48345. 
Tyagi, S., Gupta, P., Saini, A.S., Kaushal, C., Sharma, S., 2011. The peroxisome proliferator-activated receptor: A 
family of nuclear receptors role in various diseases. Journal of Advanced Pharmaceutical Technology & Research 2, 
236-240. 
Upadhyay, H.C., Dwivedi, G.R., Roy, S., Sharma, A., Darokar, M.P., Srivastava, S.K., 2014. Phytol Derivatives as 
Drug Resistance Reversal Agents. ChemMedChem 9, 1860-1868. 
van den Brink, D.M., van Miert, J.N., Dacremont, G., Rontani, J.F., Wanders, R.J., 2005. Characterization of the 
final step in the conversion of phytol into phytanic acid. The Journal of biological chemistry 280, 26838-26844. 
van den Brink, D.M., Wanders, R.J., 2006. Phytanic acid: production from phytol, its breakdown and role in human 
disease. Cellular and molecular life sciences : CMLS 63, 1752-1765. 
Vieweg, W.V.R., Julius, D.A., Fernandez, A., Beatty-Brooks, M., Hettema, J.M., Pandurangi, A.K., 2006. 
Posttraumatic Stress Disorder: Clinical Features, Pathophysiology, and Treatment. The American Journal of 
Medicine 119, 383-390. 
Wanders, R.J.A., Komen, J., Ferdinandusse, S., 2011. Phytanic acid metabolism in health and disease. Biochimica et 
Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1811, 498-507. 
Wang, J., Hu, X., Ai, W., Zhang, F., Yang, K., Wang, L., Zhu, X., Gao, P., Shu, G., Jiang, Q., Wang, S., 2017. 
Phytol increases adipocyte number and glucose tolerance through activation of PI3K/Akt signaling pathway in mice 
fed high-fat and high-fructose diet. Biochemical and biophysical research communications 489, 432-438. 
Yu, S., Reddy, J.K., 2007. Transcription coactivators for peroxisome proliferator-activated receptors. Biochimica et 
Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1771, 936-951. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
28 
Zakusov, V., Ostrovskaya, R., Kozhechkin, S., Markovich, V., Molodavkin, G., Voronina, T., 1977. Further 
evidence for GABA-ergic mechanisms in the action of benzodiazepines. Arch Int Pharmacodyn Thérap 229, 313-
326. 
Zhang, Y., Liu, X., Wang, Y., Jiang, P., Quek, S., 2016. Antibacterial activity and mechanism of cinnamon essential 
oil against Escherichia coli and Staphylococcus aureus. Food Control 59, 282-289. 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
29 
 
FIGURE 1. A salvage pathway of PYT metabolism. Phylloquinone, tocopherol, PYT-fatty 
acid ester, and other degradation products are known to be of phytyl-PP origin, which can be 
synthesized through the mevalonate or methyl-erythritol-phosphate pathway (Ischebeck et al., 
2006; Islam et al., 2015).   
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FIGURE 2.  ω-Oxidation products of phytanic acid. Production of small and medium chain 
fatty acids with subsequent degradation to CO2 and H2O in mitochondria (Islam et al., 2015; 
Wanders et al., 2011). 
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FIGURE 3. Phytol mediated antioxidant mechanisms. A. Free radical pathway: neutralization 
of oxidisable radicals by hydrogen radicals formation from different positions; B. Ionization 
pathway: neutralization of oxidisable anion through the liberated proton from alcoholic (OH) 
group.   
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FIGURE 4. Mechanism of apoptosis and autophagic effects of phytol. 
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Table 1. Summary of bioactivity studies of phytol and its derivatives 1 
 2 
Tested compound Dose Tests  Results  References   
Phytol 
62.5, 125, 250, 
500 and 1000 
µg/mL 
Antimicrobial test against Escherichia coli 
(ATCC-25922), Staphylococcus aureus 
(ATCC-25923), Aspergillus niger (ATCC-
16888), and Candida albicans (ATCC- 
10231). 
MIC: 62.5 µg/mL (E. coli, C. albicans, 
and A. niger) 
MIC: >1000 µg/mL (S. aureus) (Ghaneian et al., 2015) 
62.5, 125, 250, 
500 and 1000 
µg/mL 
Toxicity on mouse skin cell suspension 
Time and dose-dependent toxicity. 
Decrease of incubation time led to an 
increase of cell viability 
Phytol  
0.5, 0.25 and 
0.125 µg/mL of 
MIC (MIC was 
19 µg/mL) 
Anti-quorum sensing activity against 
Pseudomonas aeruginosa (in vitro) 
Ability to reduce  P. aeruginosa biofilm 
formation as well as twitching and 
flagella motility 
(Pejin et al., 2015) 
Phytol  0.15 to 160 µg/mL 
Antibacterial activity against S. aureus 
(FDA209P) 
Inhibitory activity on the growth within 
the range of 1.25 to 40 µg/mL (Inoue et al., 2005) 
Phytol 0 to 200 µM (24 h) 
Cytotoxic activity in human gastric 
adenocarcinoma AGS cells 
Anti-proliferative activity associated 
with autophagy induction with increase 
in acidic vesicular organelles formation  
(Song and Cho, 2015) 
Phytol  25, 50, 100, and 200 mg/kg (i.p.) 
Antinociceptive (mice) and antioxidant 
tests 
Antinociceptive and antioxidant activity 
in a dose-dependent manner (Santos et al., 2013) 
Phytol  10-100 µM  Anticancer test in lymphoid leukemia Molt 4B cells 
Growth inhibition of Molt 4B cells due 
to the induction of apoptosis (Komiya et al., 1999) 
Phytol  0.5 µg/kg (per 
week) (i.p.) 
Histological evaluation of Sprague-Dawley 
rats (female) mammary tumours 
Inhibition of  progression of MNU-
induced tumours in mammary gland, 
along with decreased tumour volume 
(Líška et al., 2011) 
Phytol  50 - 200 mg; topically (16 w) 
Tumor promoter test in Female ICR mice 
skin Weak tumor promoter activity (Kagoura et al., 1999) 
Phytol  20, 40, 80 and 100 µM (24 h) 
Antitumor mechanism of PYT in Huh7 
and HepG2 cells 
Antitumor activity via apoptosis 
induction through activation of caspase-
9/3 and inhibition of EMT in 
hepatocellular carcinoma cells 
(Kim et al., 2015) 
Phytol  25, 50 and 75 
mg/kg (i.p.) Anticonvulsant effect in Swiss mice 
Anticonvulsant activity in a dose-
dependent way by modulating of 
neurotransmitter systems 
(Costa et al., 2012) 
Phytol  1 and 2 µM Anticancer test in MDA-MB-231breast 
cancer cell line  
Inhibition of the MDA-MB-231 cell 
line invasiveness  (Chikati, 2013) 
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Phytol  
5 and 10 mg/kg 
(dissolved in 5% 
cremophor) 
(p.o.) 
Anti-scratching behavioral test in ICR and 
BALB/c mice 
Improving scratching behavior by 
inhibiting the allergic cytokines 
expression through NF-κB regulation in 
skin 
(Ryu et al., 2011) 
Phytol  0.5%, 1%, or 2% (p.o.) (7 d) 
NAD synthesis and ACMSD expression in 
male Sprague-Dawley rats 
Decrease of ACMSD activity and its 
mRNA expression in a dose-dependent 
manner in liver and in primary rat 
hepatocytes 
(Matsuda et al., 2013) 
Phytol  7.5, 25, 50, and 75 mg/kg (i.p.) 
Anti-inflammatory test in mice (paw 
edema induced by diverse inflammatory 
agents) 
Decrease of inflammatory response by 
inhibiting neutrophil migration partly 
caused by reduction in IL-1-beta and 
TNF-α levels 
(Silva et al., 2014) 
Phytol  25, 50 and 75 
mg/kg (i.p.) Anxiolytic-like effects in Swiss mice 
Sedative and anxiolytic-like effects 
probably due to interaction with 
GABAA receptor 
(Costa et al., 2014) 
Phytol 
12.5 to 100 
µg/mL 
Activity against Schistosoma mansoni 
worms (in vitro) Death and reduced motor activity of the 
worms (in vitro), and worm burden 
reduction in the infected mice (in vivo) 
(de Moraes et al., 2014) 
40 mg/kg (p.o.) Test in Balb/c mice infected with S. 
mansoni  
Pivaloyl, 3,4,5-
trimethoxybenz
oyl, 2,3-
dichlorobenzoy, 
cinnamoyl 
derivatives of 
phytol 
Serial dilutions Drug resistance reversal test against E. coli (CA8000 and DH5 alpha) 
Drug resistance reversal activity (up to 
16-fold activity potentiation) (Upadhyay et al., 2014) 
Phytol rich 
hexane fraction 
of Lacistema 
pubescens 
5 to 111 µg/mL Anti-promastigote and anti-amastigote 
assays with Leishmania amazonensis 
Anti-promastigote and anti-amastigote 
activity in L. amazonensis with IC50 
values of 44.0 and 25.8 µg/mL, 
respectively 
(da Silva et al., 2015) 
Phytanic acid 50 µM Mitochondria from brain and heart of adult 
rats 
Rotenone-like oxidative stress via a 
direct action on mitochondria (Schönfeld and Reiser, 2006) 
Phytanic acid 10 µM Effects of PA on mouse neuroblastoma Neuro2a cells Cell death via activation of Hdac2, 3 (Nagai, 2015) 
Phytanic acid 1-500 µM Effects of PA in Wistar male rats 
cerebellum and cerebral cortex 
Increase of TBA-RS levels in both 
cerebellum and cerebral cortex 
significantly diminished GSH 
concentration 
(Leipnitz et al., 2010) 
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Phytol and 
phytanic acid 
Phytol: 500 
mg/kg (p.o.) and 
phytanic acid 
100 mg/kg (p.o.) 
Anti-teratogenic activity in mice (female) Reduction of teratogenesis caused by 
retinol (Arnhold et al., 2002) 
Phytanol and 
phytanyl 
chloride 
44 mg per mice 
(i.p.) 
Immunoadjuvant activity in mice exposed 
to Staphylococcus aureus 
Strong induction of the protective 
cytokines IL-17 and IL-1β and 
enhancement of the anti-S. aureus 
immune response 
(Roy Chowdhury et al., 2013) 
Phytanol, 
phytanyl amine  
Phytanol: 40 mg 
(i.p.); 
Phytanyl amine: 
5 mg (i.p.) 
Immunoadjuvant effects in BALB/c mice 
Activation of neutrophils and 
monocytes, release of B-lymphocyte 
chemo-attractant (BLC), and enhanced 
expression of NLRP genes including 
NLRP3 
(Aachoui et al., 2011a) 
Phytanol, 
phytanyl amine  
Phytanol: 40 mg 
(i.p.); 
Phytanyl amine: 
2.5 mg (i.p.) 
Immunoadjuvant activity in C57Bl/6 and 
BALB/c mice  
Increase of immunogen-specific IgG1 
and IgG2a antibody responses, 
modulatory immune response through 
apoptotic/necrotic effects on target 
tumor cells 
(Aachoui et al., 2011b) 
Phytol, phytanic 
acid and 
pristanic acid 
3, 10 and 30 µM Immunomodulatory activity on mouse 
splenocytes stimulated by T-cell mitogens 
Reduction of IFN-γ, IL-4, and IL-10 by 
all the test substances and IL-17A by 
PYT and PA 
(Nakanishi et al., 2016) 
Phytol 250 mg/kg (p.o.) Anti-diabetic test in adult male Wistar 
albino rats 
Insulin-sensitizing/anti-diabetic effect 
of PYT via nuclear receptors activation 
and heterodimerization of RXR with 
PPARγ by PA 
(Elmazar et al., 2013) 
 3 
Table 2. Summary of test dose/conc., test system(s) and active dose/conc. of phytol and its derivatives 4 
 5 
Phytol and/or its 
derivatives 
Tested 
dose/Conc. Test system(s) Active dose/conc. References  
 
Phytol 
62.5, 125, 250, 
500 and 1000 
µg/mL 
Escherichia coli, Staphylococcus aureus, 
Aspergillus niger, and Candida albicans 62.5 &  >1000 µg/mL 
(Ghaneian et al., 2015) 62.5, 125, 250, 
500 and 1000 
µg/mL 
Mouse skin suspension 62.5 - 1000 µg/mL 
Phytol  
0.5, 0.25 and 
0.125 µg/mL 
of MIC  
Pseudomonas aeruginosa  19 µg/mL (Pejin et al., 2015) 
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Phytol  
0.15, 0.30, 
0.60, 1.25, 
2.50, 5.0, 10, 
20, 40, 80 160 
µg/mL 
S. aureus 0.15 µg/mL (Inoue et al., 2005) 
Phytol 
12.5, 25, 50, 
100 and 200 
µM 
Human gastric adenocarcinoma AGS cells 12.5 - 200 µM (Song and Cho, 2015) 
Phytol  
In vivo: 25, 50, 
100, and 200 
mg/kg (i.p.); 
In vitro: 0.9, 
1.8, 3.6, 5.4 
and 7.2 ng/mL 
In vivo: Swiss albino mice (n = 8);  
In vitro: TBARS, NO and OH scavenging 
assay 
In vivo: 50 – 200 mg/kg; 
In vitro: 0.9 – 5.4 ng/mL (Santos et al., 2013) 
Phytol  10, 20, 40, 80 
and 100 µM  Lymphoid leukemia Molt 4B cells 20 – 100 µM (Komiya et al., 1999) 
Phytol  0.5 µg/kg (per 
week); i.p. Sprague-Dawley female rats 0.5 µg/kg (Líška et al., 2011) 
Phytol  50, 100, 150 
and 200 mg Female ICR mouse skin 50 - 200 mg (Kagoura et al., 1999) 
Phytol  20, 40, 80 and 100 µM  Huh7 and HepG2 cells 20 – 100 µM (Kim et al., 2015) 
Phytol  25, 50 and 75 
mg/kg (i.p.) Swiss mice (n = 24) 25 – 75 mg/kg (Costa et al., 2012) 
Phytol  1 and 2 µM MDA-MB-231breast cancer cells 1 -2 µM (Chikati, 2013) 
Phytol  
5 or 10 mg/kg 
(in 5% 
cremophor; 
p.o.) 
ICR and BALB/c mice (n = 6) 5 and 10 mg/kg (Ryu et al., 2011) 
Phytol  0.5, 1, or 2%; p.o. (7 d) Male Sprague-Dawley rats (n = 6) 0.5 – 2% (Matsuda et al., 2013) 
Phytol  7.5, 25, 50 and 75 mg/kg (i.p.) Swiss albino mice (n = 5) 7.5 – 75 mg/kg (Silva et al., 2014) 
Phytol  25, 50 and 75 
mg/kg (i.p.) Swiss albino mice (n =7 ) 25 – 75 mg/kg (Costa et al., 2014) 
Phytol 
12.5, 25, 50, 
75 and 100 
µg/mL 
Schistosoma mansoni  50 - 100 µg/mL & 40 mg/kg (de Moraes et al., 2014) 
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40 mg/kg 
(p.o.) Balb/c mice infected with S. mansoni  
Phytol rich 
hexane fraction of 
Lacistema 
pubescens 
5 to 111 
µg/mL Leishmania amazonensis 25.8 – 44.0 µg/mL (da Silva et al., 2015) 
Phytanic acid 50 µM Rat mitochondria from brain and heart 50 µM (Schönfeld and Reiser, 2006) 
Phytanic acid 10 µM Mouse neuroblastoma Neuro2a cells 10 µM (Nagai, 2015) 
Phytanic acid 1, 10, 100 and 500 µM 
Wistar male rats cerebellum and cerebral 
cortex 100 & 500 µM (Leipnitz et al., 2010) 
Phytol and 
phytanic acid 
Phytol: 500 
mg/kg  (p.o.) 
and phytanic 
acid 100 
mg/kg (p.o.) 
Anti-teratogenic activity in female mice Phytol at 500 mg/kg;  Phytanic acid at 100 mg/kg (Arnhold et al., 2002) 
Phytanol and 
phytanyl chloride 
44 mg per 
mice (i.p.) Mice exposed to S. aureus 44 mg (Roy Chowdhury et al., 2013) 
Phytanol, 
phytanyl amine  
Phytanol: 40 
mg (i.p.) 
Phytanyl 
amine: 5 mg 
(i.p.) 
BALB/c mice (n = 3) Phytanol: 40 mg; Phytanyl amine: 5 mg (Aachoui et al., 2011a) 
Phytanol, 
phytanyl amine  
Phytanol: 40 
mg (i.p.), 
Phytanyl 
amine: 2.5 mg 
(i.p.) 
C57Bl/6 and BALB/c mice (n = 6) Phytanol: 40 mg; Phytanyl amine: 2.5 mg (Aachoui et al., 2011b) 
Phytol, phytanic 
acid and pristanic 
acid 
3, 10 and 30 
µM 
Mouse splenocytes stimulated by T-cell 
mitogens 
Phytol: 30 µM; 
Pristanic acid: 10 and 30 µM (Nakanishi et al., 2016) 
Phytol 250 mg/kg (p.o.) Male Wistar albino rats (n = 20/80) 250 mg/kg (Elmazar et al., 2013) 
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